LB Pharmaceuticals Inc. (LBRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 1-Year High – Here’s What Happened
LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report)'s stock price hit a new 52-week high during trading on Friday. The stock traded as high as $26.26 and last traded at $26.2950, with a volume of 47974 shares. The stock had previously closed at $24.94. Analyst Upgrades and Downgrades A number of equities analysts have
LB Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 200,000 | $3.16M | $6.32M | $3.16M | 100.19% |
| NM Nir Messafi Deep Track Capita LLP | 3.35M | $52.94M | $106.18M | $53.24M | 100.57% |
 Joseph Castro Nuveen LLC | 22,966 | $511,223 | $733,763.7 | $222,540.7 | 43.53% |
 Kevin Roan Stempoint Capita LLP | 50,000 | $1.23M | $1.61M | $374,015 | 30.33% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 34,003 | $536,902 | $1.05M | $512,277.57 | 95.41% |
LB Pharmaceuticals Inc. (LBRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LB Pharmaceuticals Inc. ever had a stock split?
LB Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Heather D. Turner CEO | NASDAQ (NMS) Exchange | 50180M108 CUSIP |
| US Country | 27 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
This clinical-stage biopharmaceutical company is dedicated to the innovation and development of novel therapies aimed at treating neuropsychiatric diseases, which include disorders such as schizophrenia and bipolar depression. As a pioneer in the field, the company is committed to addressing the unmet needs of patients suffering from these conditions by leveraging cutting-edge research and drug development methodologies. Its rigorous clinical trials are focused on creating effective and safe treatment options that can significantly improve the quality of life for those affected by such challenging mental health issues.
Products and Services
- LB‑102: A lead candidate therapy, LB-102 is a methylated derivative of amisulpride, specifically designed to offer enhanced therapeutic benefits for individuals suffering from neuropsychiatric disorders. The drug's formulation aims to improve efficacy while minimizing side effects typically associated with traditional treatments.
